Divergent Transcriptomic Effects of Allopregnanolone in Postpartum Depression

Divergent Transcriptomic Effects of Allopregnanolone in Postpartum Depression

Brexanolone, a formulation of the neurosteroid allopregnanolone (ALLO), is approved for treating postpartum depression (PPD) and is being investigated for therapeutic efficacy across numerous neuropsychiatric disorders. Given ALLO’s beneficial effects on mood in women with PPD compared to healthy co...

Full description

Bibliographic Details
Main Authors: Sarah A. Rudzinskas, Maria A. Mazzu, Crystal Edler Schiller, Samantha Meltzer-Brody, David R. Rubinow, Peter J. Schmidt, David Goldman
Format: Article
Language:English
Published: MDPI AG 2023-06-01
Series:Genes
Subjects:
postpartum depression
allopregnanolone
transcriptomics
neurosteroids
<i>GAD1</i>
Online Access:https://www.mdpi.com/2073-4425/14/6/1234

Internet

https://www.mdpi.com/2073-4425/14/6/1234

Similar Items